ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1488	National Cancer Institute	Html	en	Metastatic Squamous Neck Cancer With Occult Primary Treatment (PDQ®)–Health Professional Version	Metastatic squamous neck cancer with occult primary occurs when squamous cell cancer spreads to lymph nodes in the neck from an undetectable primary tumor. Treatment includes surgery and radiation therapy. Learn about the diagnosis, survival, staging, and treatment of these tumors.	primary site. 0.436234 moderately differentiated tumors 0.539497 Thyroid function testing 0.46762 massive homolateral adenopathy 0.465434 EBV genomic material 0.535385 metastatic carcinoma 0.482369 lymph node dissection 0.549764 probable primary site 0.571551 germ cell tumor 0.575226 PDQ cancer information 0.618029 cervical lymph nodes. 0.554105 poorly differentiated tumors 0.545473 entire thyroid gland 0.457464 cancer information summary 0.595141 Primary tumors 0.485135 palpable tumor 0.472764 breast cancer prevention 0.4696 adequate neck dissection 0.527836 primary physician 0.522652 patients 0.45154 poorly differentiated tumor 0.752934 fine-needle aspiration biopsy 0.484684 epstein-barr virus 0.506145 NCI PDQ cancer 0.504517 lower neck 0.447545	radiation therapy 0.728398 cervical nodal tissue 0.52026 squamous carcinoma 0.531992 magnetic resonance imaging 0.467707 neck mass 0.432409 DNA amplification 0.492378 metastatic squamous cell 0.564542 neck primary site 0.62075 germ cell malignancies 0.487658 metastatic lymph node 0.63625 overt nasopharyngeal carcinoma. 0.485019 cervical lymph node 0.754988 obvious metastatic disease 0.554252 polymerase chain reaction 0.487648 cervical node metastases 0.558588 Squamous carcinomas 0.45824 external-beam radiation therapy 0.502847 Periodic Acid Schiff 0.471213 unknown primary 0.44413 platinum-based combination chemotherapy 0.478329 undifferentiated carcinoma 0.456062 neck tumors 0.464529 occult primary tumor 0.948651 lymph node metastases 0.623031	CLICK HERE
1558	National Cancer Institute	Html	en	Endometrial Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease.	cancer treatment 0.459672 cancer prevention trials 0.519855 estrogen 0.503683 endometrial cancer prevention 0.633127 protective factors 0.494311 following PDQ summaries 0.487054 PDQ cancer information 0.583616 estrogen receptor modulators 0.479388 oral contraceptives increases 0.455046 uterus 0.455824 clinical trials 0.591442 cancer information summary 0.536389 breast cancer prevention 0.515055 cancer patients 0.456862 cancer risk factor 0.514935 NCI’s PDQ 0.460213 metabolic syndrome 0.469608 Clinical Trials section 0.455747 NCI PDQ cancer 0.511939 endometrial hyperplasia 0.525569 hormone replacement therapy 0.4814 new cases 0.45495 estrogen levels 0.496361 cancer risk factors 0.513284	Cancer prevention 0.648371 cancer protective factor 0.491722 high estrogen levels 0.479463 Cancer Information Service 0.48404 polycystic ovary syndrome 0.484739 prevention clinical trials 0.493334 Prevention Editorial Board 0.485326 treatment clinical trials 0.456257 National Cancer Institute 0.542099 endometrial cancer 0.951484 African American women 0.525683 estrogen therapy 0.459908 higher risk 0.454955 postmenopausal women 0.557323 Cancer Care page 0.476271 PDQ database 0.456704 PDQ summary 0.495085 combination oral contraceptives 0.477913 cancer clinical trials 0.489805 risk factors 0.587492 nonpolyposis colon cancer 0.481746 cancer information summaries 0.48866 comprehensive cancer information 0.488387 risk 0.63452	CLICK HERE
1738	National Cancer Institute	Html	en	Angiogenesis Inhibitors	A fact sheet that describes the process of eliminating the blood supply to tumors. Lists the cancers in which this approach is being tested.	downstream signaling pathways 0.352285 cancer treatments 0.343078 endothelial cells 0.425301 normal endothelial cells 0.371999 ongoing clinical trials 0.354207 tumor blood vessels 0.37481 chemical signals 0.419755 Drug Administration 0.362362 nearby normal cells 0.358821 endothelial growth factors 0.369707 cancer cells 0.356859 VEGF receptor 0.345762 angiogenesis inhibitors 0.944406 inhibiting effects 0.333711 Finding NCI-Supported Clinical 0.352444 antiangiogenic agents 0.332621 synthetic angiogenesis inhibitors 0.552673 angiogenesis pathways 0.444579 new blood vessels 0.642431 endothelial growth factor 0.370427 rare side effects 0.352056 tumor-vascular disrupting agents 0.351163 tumor angiogenesis 0.466745 nci-supported clinical trials 0.386702	treatment clinical trials 0.356002 blood vessel growth 0.362373 metastatic colorectal cancer 0.362717 tumor growth 0.335181 clinical trials 0.464552 tumor cells 0.336152 U.S. Food 0.362379 renal cell cancer 0.360541 VEGF 0.349952 blood vessels 0.736003 angiogenesis inhibitor therapy 0.559395 blood vessel formation 0.363763 non-small cell lung 0.351539 normal body processes 0.348332 kidney cancer 0.365728 NCI Contact Center 0.349609 tumors 0.369989 cancer clinical trials 0.389068 blood supply 0.372039 human cancer 0.334753 conventional anticancer drugs 0.349958 cancer 0.433974 growth 0.373337	CLICK HERE
1881	National Cancer Institute	Html	es	Tratamiento del sarcoma de Ewing (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del Sarcoma de Ewing.	ewing sarcoma 0.997403 Ewing family 0.318421 Ewing's sarcoma family 0.369762 metastatic ewing sarcoma 0.318472 ewing óseo valor 0.311245 skeletal localized ewing 0.310397 Ewing Grupo 0.309837 non-metastatic ewing 0.310313 Ewing's Sarcoma Studies 0.319442 ewing óseo característica 0.311302 Ewing extraóseo 0.331665 Ewing sarcoma demonstrates 0.319966 Ewing sarcoma with 0.320002 localized ewing tumours 0.310538 localized ewing 0.369471 ewing-like sarcomas 0.313809 Children's Oncology Group 0.332597 ewing sarcoma family 0.424972 Ewing sarcoma patients 0.320654 with ewing 0.35586 Ewing's tumors with 0.311931 Ewing Sarcoma Study 0.321953 with localized ewing 0.320841 primary ewing 0.310256 extraskeletal ewing sarcoma 0.318994	Ewing's Sarcoma Study 0.335323 synovial sarcoma 0.309759 cooperative ewing sarcoma 0.431437 Ewing sarcoma under 0.319395 EWSR1-rearranged Ewing 0.309748 localized ewing tumor 0.320103 ewing extraóseo sarcoma 0.320923 osseous ewing 0.30998 Pediatr Blood Cancer 0.363663 ewing sarcoma defines 0.332159 Intergroup Cooperative Ewing 0.343374 Ewing Sarcoma Studies 0.337882 Genes Chromosomes Cancer 0.320148 ewing's sarcoma 0.626467 Ewing óseo 0.324425 gen ewsr1 0.309831 ewing's tumors 0.326472 secondary ewing 0.310067 Pediatr Hematol Oncol 0.310262 Clin Oncol 0.365031 multifocal ewing sarcoma 0.318953 ewing tumors 0.399514 congenital ewing sarcoma 0.318921 Ewing sarcoma susceptibility 0.318556	CLICK HERE
1991	National Cancer Institute	Html	es	Tratamiento del tumor teratoideo/rabdoide atípico del sistema nervioso central infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores teratoideos/rabdoides atípicos del sistema nervioso central infantil	Children’s Cancer Group 0.214389 Brain Tumor Registry 0.228944 Blaney S 0.21303 tumor or malignant 0.212972 highly malignant tumor 0.212766 CNS atypical teratoid 0.213711 nervous system atypical 0.507412 childhood atypical teratoid 0.213555 Instituto Nacional 0.211549 renal rhabdoid tumor 0.229121 teratoid rhabdoid tumours 0.215084 central nervous system 0.954132 rhabdoid tumors 0.527901 atypical teratoid 0.31284 nervous system malignant 0.215465 malignant rhabdoid tumor 0.241559 non-rhabdoid tumor with 0.213028 brain tumor consortium 0.236375 with central nervous 0.221866 Pediatric MATCH 0.208336 system atypical teratoid 0.255953 Children’s Oncology Group 0.209584 Cribriform neuroepithelial tumor 0.211375 with newly 0.207496 teratoid rhabdoid tumors 0.315276	Pediatr Blood Cancer 0.255454 Genes Chromosomes Cancer 0.225267 National Cancer Institute 0.207929 chemotherapy with autologous 0.210383 PDQ Tratamiento 0.209709 Tumor Registry 0.24792 Packer RJ 0.213353 tumor consortium study 0.212376 Pediatr Hematol Oncol 0.251621 Clin Oncol 0.239466 sistema nervioso central 0.330207 patient with 0.207449 brain tumor 0.273366 Pediatric Oncology Group 0.209965 with autologous hematopoietic 0.20843 Germline INI1 mutation 0.207759 with relapsed or 0.208722 término tumor 0.213201 atypical teratoid tumor 0.230394 newly diagnosed 0.211587 Austrian Brain Tumor 0.226397 Oncology Group 0.212124 tumor showing retained 0.210972 pediatric brain tumor 0.239731	CLICK HERE
2006	National Cancer Institute	Html	es	Tratamiento del feocromocitoma y paraganglioma (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del feocromocitoma y el paraganglioma.	glándula tiroides 0.609278 glándulas suprarrenales ayuda 0.631749 siguientes procedimientos 0.696393 siguientes aspectos 0.575361 Neurofibromatosis tipo 0.579395 siguientes síndromes 0.595261 vía oral 0.53652 rayos x 0.649118 tumores neuroendocrinos 0.602024 National Cancer Institute 0.520886 paraganglioma causa efectos 0.753898 siguientes riesgos 0.518888 endocrina múltiple tipo 0.630502 feocromocitoma hereditario 0.929917	Instituto Nacional 0.540854 PDQ Tratamiento 0.549585 insuficiencia suprarrenal aguda 0.595836 Mucha sudación 0.56538 partes distantes 0.527507 Physician Data Query 0.586955 siguientes situaciones 0.586373 siguientes características 0.581278 von hippel-lindau 0.636326 TEP -FDG 0.553345 enfermedad.ampliar paraganglioma 0.655429 Períodos súbitos 0.521079 siguientes medicamentos 0.565161 siguientes pruebas 0.590766	CLICK HERE
2060	National Cancer Institute	Html	es	Cuidados paliativos durante el cáncer	Describe la función de los cuidados paliativos, los cuales son los cuidados que se brindan a pacientes que tienen una enfermedad grave o potencialmente letal, como el cáncer, desde el momento del diagnóstico y durante todo el curso de la enfermedad.	Cáncer patrocina investigación 0.300839 Cáncer Servicios 0.300985 Palliative Care Organization 0.300646 siguientes problemas 0.300582 cuidado médico 0.300437 familiar enfermo 0.300321 Palliative Care 0.301049 amplia gama 0.300339 profesional médico 0.30124 Advance Palliative Care 0.300677	National Hospice 0.300346 largo plazo 0.3012 profesionales médicos 0.301302 Whole Patient 0.300325 Cáncer Etapa final 0.301212 cuidados paliativos 0.999612 National Cancer Institute 0.300463 resultado necesidades 0.300363 seguro médico 0.301606	CLICK HERE
2071	National Cancer Institute	Html	es	Cirugía para reducir el riesgo de cáncer de seno	Hoja informativa que describe las clases de cirugía para reducir el riesgo de cáncer de seno y las situaciones en las que se puede pensar en esas operaciones.	Surgical Adjuvant Breast 0.526694 PROSE Study Group 0.516256 cáncer invasor 0.567762 brca1 or brca2 0.538495 mastectomía subcutánea 0.530865 Preventing breast 0.511838 Breast Cancer Research 0.523551 risk-reducing surgery 0.507962 with brca1 or 0.509298 brca2 mutation 0.564149 breast screening with 0.51472 Preventive Services Task 0.512338 mastectomy reduces breast 0.516804 alta penetrancia 0.508455 risk after smaller 0.509063 Friebel T 0.508008 PubMed Abstract 0.952028 Clinical Oncology 0.653359 Cancer Journal 0.515034 BRCA2 mutation carriers 0.554396 early breast cancer 0.539203 ¿Cuáles mujeres 0.517292 bilateral mastectomy 0.517477 BRCA2 mutations detected 0.508495 alto riesgo 0.656597	Wickerham DL 0.51571 an overview 0.508367 Costantino JP 0.515178 Cancer Risk Assessment 0.519342 Rebbeck TR 0.508232 developing invasive breast 0.513495 antecedentes familiares 0.554456 riesgo promedio 0.539499 or brca2 mutations 0.536318 breast cancer risk 0.617067 mutation carriers with 0.509322 gen pten 0.510383 breast cancer 0.801718 Breast Cancer Trialists 0.522907 Services Task Force 0.511925 prophylactic mastectomy 0.591377 mujeres portadoras 0.533011 gen brca1 0.561202 contralateral prophylactic mastectomy 0.534028 Cancer Institute 0.511805 Clinical Cancer Research 0.516971 gen brca2 0.561192 gen tp53 0.518098 New England Journal 0.535054	CLICK HERE
2958	National Cancer Institute	Html	en	Making a Quit Plan	Planning ahead improves your chances of quitting smoking for good. Follow these steps to create your own individual quit plan.	health care provider 0.682085 common smoking reminders 0.549 ashtrays 0.452031 easy steps 0.487737 NRT 0.496038 healthy snacks 0.472018 energy level 0.475958 special treat 0.473544 word QUIT 0.556414 nicotine replacement therapy 0.840728 items—like straws 0.475777 quit plan 0.979663 favorite songs 0.473638 triggers 0.466512 list 0.464107 text message 0.469947 friends 0.440731 online chat 0.467529 chances 0.434282 young adults 0.470223 cigarettes 0.452193 monitor progress 0.465509 big accomplishment 0.488463 United States 0.472032 smoke breaks 0.469072	regular exercise 0.473275 National Cancer Institute 0.530065 NCI LiveHelp page 0.544024 text messaging service 0.527129 craving 0.4367 good mood 0.477991 cravings 0.511271 Smokefree Apps help 0.573957 movie night 0.475119 Nicotine withdrawal 0.548423 Practice deep breathing 0.541377 cigarette money 0.475711 huge achievement 0.482604 Eastern Time 0.480147 nicotine gum 0.500974 different pleasure 0.478743 cigarette butts 0.473635 withdrawal symptoms 0.585184 activities 0.427718 smokefree milestone 0.520259 time 0.49243 online calendars 0.483411 smoking cessation counselor 0.535799 family 0.428198	CLICK HERE
16647	National Cancer Institute	Html	en	Track 1: Oncology Product Research and Review for M.D. Oncology Fellows	NCI and FDA collaborate to train physicians in clinical trials methodology and medical product development. Learn more about this cancer training program.	cancer treatment 0.479728 product development process 0.567202 review process 0.489003 oncology training programs 0.558331 FDA scientific review 0.54729 permanent residency 0.47764 Medical Center Dr 0.53143 application guidelines 0.474013 continued clinical activities 0.563939 research goals 0.484402 clinical trials methodology 0.592427 post-marketing surveillance 0.480689 Regulatory Review Fellowships 0.542695 Cancer Training 0.476448 wide variety 0.47699 basic science 0.47529 clinical research 0.572543 clinical pharmacology 0.56636 clinical aspects 0.565731 Review list 0.477947 application materials 0.475814 regulatory pathways 0.4862 U.S. citizenship 0.479791 practical experience 0.477134 cancer product development 0.582309	earliest start date 0.532518 regulatory aspects 0.552684 critical ethical issues 0.546923 medical product development 0.68682 product research 0.503682 board eligibility 0.486187 product development research 0.56952 internal medicine 0.479825 clinical trial design 0.90418 oncology subspecialty 0.512496 new product development 0.559224 epidemiology 0.43097 product development 0.772741 senior member 0.472136 radiation oncology 0.485841 human research subjects 0.561696 Clinical training 0.523355 course work 0.477251 drug regulation 0.476113 basic bench science 0.561571 Personal statement 0.473214 Office Phone 0.471769 NCI-FDA Research 0.483426 new agents 0.475146	CLICK HERE